A Phase 2, Multicenter, Open-label Study to Measure the Safety of Extending Preservation and Assessment Time of Donor Lungs Using Normothermic Ex Vivo Lung Perfusion and Ventilation (EVLP) as Administered by the SPONSOR Using the Toronto EVLP System™
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 118
- 试验地点
- 16
- 主要终点
- Count of Participants With Primary Graft Dysfunction (PGD), Grade 3
研究概览
简要总结
This is a safety study to compare the safety of receiving a lung treated with the Toronto EVLP System™ by SPONSOR in SPONSOR's dedicated facility against standard lung transplantation.
详细描述
Human donor lungs allocated to a participating study transplant center (Study Center) for a specific recipient and meeting study EVLP donor lung inclusion/exclusion criteria will be assessed by SPONSOR for inclusion into the study.
Upon retrieval, donor lung(s) will be packaged and transported on ice to the SPONSOR's EVLP facility in Silver Spring, Maryland, no differently than when lungs are recovered, packaged, and transported to any transplant center for implantation.
The EVLP procedure will be performed by Certified Ex Vivo Lung Specialists using the Toronto EVLP System™ for up to 6 hours, collecting and relaying lung function assessment data hourly or as requested by the Study Center transplant surgeon. Additionally, the Study Center surgeon will have the capability to evaluate lung function data and monitor the procedure remotely through a dedicated video link.
Upon acceptance of an EVLP donor lung by the Study Center, the single lung or lung block is cooled down by the Toronto EVLP System™ to 10 degrees C. Thereafter, perfusion and ventilation are stopped and the lung is prepared for hypothermic storage and transport to the accepting Study Center.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject Inclusion Criteria:
- •In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- •Male or female patients
- •All patients, 18 years of age or older
- •Patient already on or added to the active waiting list for a single or bilateral lung transplant
- •Patient or patient's representative provides informed consent for participation in the study at the time of study commencement or time of listing for transplant
- •Patient or patient's representative reconfirms informed consent for the study on the day of lung transplant
排除标准
- •A subject who meets any of the following criteria will be excluded from participation:
- •Patients listed for same-side lung re-transplantation
- •Patients listed for multiple organ transplantation including lung and any other organ
- •Patients listed for live donor lobar transplant
- •Patients with HIV, active Hepatitis B/C, or Burkholderia Cepacia
- •Patients not initially consented into the study prior to the time of lung transplant
- •Patients in the ICU at the time of initial lung offer requiring mechanical ventilation, ECMO or other Extracorporeal life support (ECLS).
- •Donor Lung Inclusion Criteria for EVLP Assessment:
- •The donor lung must meet at least one of the following criteria to proceed with EVLP:
- •At the time of the clinical evaluation, the donor PaO2/FiO2 < 300 mmHg
- •Donor received ≥ 10 units of blood transfusions
- •Donation after Cardiac Death (DCD) donor
- •Expected cold ischemic time > 6 hours
- •Donor age ≥ 55 years old
- •Study Center Investigator requires additional assessment ex vivo and/or extended preservation time
- •Donor Lung Exclusion Criteria for EVLP Assessment:
- •The donor lung is excluded from EVLP if at least one of the following criteria have been met:
- •The donor lung has confirmed pneumonia and/or persistent purulent secretions identified via bronchoscopy
- •Non-persistent purulent secretions that do not clear by hour 3 on EVLP
- •The donor lung has confirmed evidence of aspiration
- •The donor lung has significant mechanical lung injury or trauma
- •The cold ischemic time, starting at donor aortic cross clamp/ initial flush (CIT-1), required to transport the lung from the donor site to start of the EVLP procedure at SPONSOR's facility > 10 hours
- •EVLP Lung Inclusion Criteria for Transplantation:
- •The donor lung must meet each of the following conditions post-EVLP for transplant suitability consideration by the Study Center Investigator:
- •PvO2/FiO2 ≥ 350 mmHg at final EVLP evaluation time period
- •and < 15% increase from baseline value (defined as the first hour collection point) to final value of pulmonary vascular resistance (PVR)
- •and < 15% increase from baseline value to final value of peak airway pressure (PawP)
- •and < 15% decrease from baseline value to final value of static lung compliance (Cstat)
- •and the total preservation time (TPT) does not exceed the following:
- •the initial CIT-1 time from donor to EVLP > 1 hour and ≤ 10 hours
- •the EVLP time > 3 hours and ≤ 6 hours
- •the second CIT-2 from EVLP cool down to beginning of recipient implantation must be > 1 hour and ≤ 6 hours for the first lung
- •the second CIT-2 from EVLP cool down to beginning of recipient implantation must be > 1 hour and ≤ 10 hours for the second lung
- •and Study Center Investigator deems lung function suitable for intended subject
- •EVLP Lung Exclusion Criteria for Transplantation:
- •The donor lung is excluded from transplant inclusion if at least one of the following criteria have been met:
- •PvO2/FiO2 < 350 mmHg at final EVLP evaluation time period
- •or ≥ 15% increase from baseline value to final value of pulmonary vascular resistance (PVR)
- •or ≥ 15% increase from baseline value to final value of peak airway pressure (PawP)
- •or ≥ 15% decrease from baseline value to final value of static lung compliance (Cstat)
- •or TPT exceeds any of the following conditions:
- •CIT-1 < 1 hour or > 10 hours
- •EVLP < 3 hours or > 6 hours
- •CIT-2 < 1 hour or > 6 hours for first lung or > 10 hours for second lung
- •or Study Center investigator deems lung function unsuitable for intended subject
研究组 & 干预措施
EVLP Double Lung Group
Toronto EVLP System™ administered to double lungs.
干预措施: Toronto EVLP System™ (Device)
Control Group
Those patients receiving a single or double lung via conventional transplant.
EVLP Single Lung Group
Toronto EVLP System™ administered to single lungs.
干预措施: Toronto EVLP System™ (Device)
结局指标
主要结局
Count of Participants With Primary Graft Dysfunction (PGD), Grade 3
时间窗: 72 Hours
Primary Graft Dysfunction is a scale published by the International Society of Heart and Lung Transplantation that uses patient oxygenation and radiographic results to score patients on a 0 (zero) to 3 (three) scale, with 3 being the most significant dysfunction.
Count of Participants Surviving
时间窗: 30 Days
The number of participants that survived to 30 days post-transplant.
次要结局
- ICU Length of Stay(30 Days)
- Time to First Extubation(Days)
- Hospital Length of Stay(Days)
- PGD Score(0, 24, 48 & 72 Hours)
- Total Lung Preservation Time (TPT)(72 Hours)